Great Bay Bio Chairman Was Awarded “Young Industrialist of Hong Kong 2020”
November 18th，2020 Press Release
Great Bay Bio Chairman Was Awarded “Young Industrialist of Hong Kong 2020”
[2020/11/18, Dongguan] We are pleased to announce that Kingsley Leung, Chairman of Great Bay Bio and Uni-Bio Science Group Limited (00690.HK) (the former parent company of Dongguan Taili Biotech Co., Ltd., which is also the subsidiary of Great Bay Bio), was awarded “Young Industrialist of Hong Kong”, at the YIAH & IOY 2020 Award Presentation Ceremony cum Dinner, held on 13 November 2020.
Mr. Kingsley Leung, Chairman of Uni-Bio Science Group, accepting the Young Industrialist Awards of Hong Kong 2020 from Mrs Carrie Lam, Chief Executive of Hong Kong
The annual Young Industrialist Awards of Hong Kong (“YIAH”) was first launched in 1988 by the Federation of Hong Kong Industries (“FHKI”). It aims to give public recognition to young industrialists who have attained outstanding achievements in their fields of industry. Through the Awards, the FHKI also aims to inspire young people to build their career in the industrial sector so as to continue the sterling work of veteran industrialists. Since the inception of YIAH in 1988, over 200 industrialists have received the Award. The awardees come from different industries and all of them demonstrate strong passion and aspiration towards the industry.
After taking the helm as Chairman of Uni-Bio Science in 2017, Mr. Leung has been dedicating to realize his vision of developing cutting-edge drugs with world-class science and technologies. Raising over RMB150M to embark on this vision, Mr. Leung started investing across the company value chain. In the R&D side, Mr. Leung relocated the group’s headquarter to Hong Kong Science Park, pioneered a new product development plan and steered the existing R&D platform towards a focus in new biologic formulation technology. In the manufacturing side, the Group put in place a new, state-of-the-art pre-filled sterile injection manufacturing line to support the commercialization of two new osteoporosis and diabetes drug. The Group has also moved the needle forward in sales & marketing by focusing more on expanding its direct sales channels, forming closer relationships with hospitals and establishing strategic partnerships with sector specific distributors to enhance sales of core products. In the end of 2019, the Group broke even for the first time and reached a new sales milestone of over RMB200M.
Mr. Kingsley Leung, Chairman of Uni-Bio Science Group, giving speech at the YIAH & IOY 2020 Award Presentation Ceremony
“Unlike traditional industries, biotechnology requires a complex knowledge base, sources of expertise are widely distributed, the locus of innovation are found in network of learning.” said Mr. Leung, “It is also a lengthy, costly and uncertain process, research and development of new products can take approximately 10 to 15 years, from discovery to commercial product launch, failure can occur at any point in the process, including in later stages after substantial investment. It is vital to have long term vision and work with many scientific collaborators in order to yield fruitful results.”
The Awards not only give recognition to the awardees’ achievements, but also highlight the industrialist’s commitment to Hong Kong’s continuing prosperity and to enable Hong Kong’s industrial development to reach new heights.
“Bio-pharmaceutical industry has benefited from groundbreaking progress in genetics, molecular biology and biochemistry over the past three decades and is revolutionizing the treatment of diseases in many major therapeutic areas globally. Many renowned biopharmaceutical giants emerged in the revolution, such as Pfizer in U.S, and Novartis in Europe. Nevertheless, we cannot find such iconic biopharmaceutical company in Hong Kong yet.” Mr. Leung added, “As biotech is burgeoning as one of the pillars of global growth, the success of biotech in HKSAR hinges on the establishment of a new Entrepreneurial culture and industrial ecosystem. We believe our business development model and experience sharing has contributed in kick-starting a new biotech culture to enhance Hong Kong’s competitiveness in the global biotech arena.”
About Young Industrialist Awards of Hong Kong
Launched in 1988 by the Federation of Hong Kong Industries (“FHKI”), the annual Young Industrialist Awards of Hong Kong (“YIAH”) give public recognition to those young industrialists, aged between 21 and 45, who have attained outstanding achievements in their fields of industry. Since the inception of YIAH in 1988, over 200 industrialists have received the Award. Since 2002, the FHKI opened nominations for the Industrialist of the Year (IOY) Award. This Award is conferred on one industrialist each year for his/her distinguished contributions to Hong Kong’s industries, economy and community, and nomination is open to industrialists of all ages. The winner is a fine example of the Hong Kong pioneering spirit and modern industrialist. Each year the panel consists of leading figures from the Government, academia and industry. The panel interviews each shortlisted candidate in person to give fair and balanced assessments to his/her achievements and contributions to ensure the Awards are conferred on the best candidates.
About Uni-Bio Science Group
Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of biopharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group has two GMP manufacturing bases in Beijing and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine as diabetes and osteoporosis, ophthalmology and dermatology. Please visit the official website of Uni-Bio Science Group for more information: www.uni-bioscience.com/
For further information, please contact:
About Great Bay Bio
Headquartered in Hong Kong, Great Bay Bio Holdings Ltd (BVI) is a newly organized high-tech enterprise dedicated to developing biotechnological services and biopharmaceutical products based on AI technology. Currently, Great Bay Bio owns several subsidiaries, including Hong Kong Great Bay Biotech Co., Ltd., Dongguan Taili Biotech Co., Ltd., and Guangzhou Taili Biomedical Technology Co., Ltd. We have invested more than USD 20 million in R&D equipment and have successfully established an independent and integrated technology platform for drug development and large-scale preparation.
The Company has been successively recognized as a "Patent Fostering Enterprise", "Patent Pilot Enterprise", "National High-tech Enterprise", "Dongguan City New Type R&D", and "Top Ten Foreign-funded R&D Center of Guangdong Province", "Guangdong Gene Engineering and Pharmaceutical Engineering Research Center, Guangdong Doctoral Workstation. Since 2006, we have undertaken several government projects and received funding from several provincial and national governments, including the "Guangdong-Hong Kong Key Breakthrough Project in Key Areas" and the "National Major New Drug Discovery Project".
For more details, please visit：www.greatbay-bio.com
Contact for business：email@example.com
Contact for media and investment: firstname.lastname@example.org